Title:
mRNA formulation development: vaccines and beyond
Abstract:
The rapid deployment of mRNA vaccines and therapeutics has been a landmark achievement in modern medicine, fundamentally enabled by the development of lipid nanoparticle (LNP) technology. These nanocarriers are meticulously engineered to overcome the formidable biological barriers facing mRNA, protecting the fragile molecule from degradation and efficiently delivering it into target cells for protein expression. The presentation will cover the intricate design principles and key considerations that underpin a successful mRNA-LNP platform, exploring optimization and design of all the LNP components for different routes of administration. Some examples of biophysical characterization assays that are crucial for understanding of structure-activity relationships will be covered. Finally, we will address the significant challenge of thermostability, discussing innovative solutions that promise to simplify cold chain logistics and broaden global access to these lifesaving therapeutics.
Bio:
Shrirang Karve, Ph.D is Global Head of Drug delivery and formulations at mRNA center of excellence, Sanofi with 12+ years of experience working on mRNA platform. Previous roles include serving as Head of delivery and formulations at Translate Bio as well as holding positions at Shire Pharmaceuticals and Dicerna. Shrirang is co-inventor on 128 patent families and has coauthored 20 + scientific publications. Shrirang received his Ph.D. from New York University and has an ALM degree from Harvard University.
1:30pm, Remsen Hall 1